StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 
 
 
Arrowhead Pharmaceut
30.49
-3.50%
 

ARWR

 

Arrowhead Pharmaceuticals

$ 30.49

 
-$1.11 | -3.50%
 
 
Open
$ 31.84
 
 
MKT CAP
$ 3.78B
 
High
$ 32.48
 
 
VOL
$ 1.40M
 
Low
$ 30.29
 
 
AVG VOL
$ 1.22M
 
 
 

ARWR Stock Analysis

  Login to display Arrowhead Pharmaceuticals (ARWR) recommendation from the last 90 days from financial news and social media.
 
 

ARWR Total Score

 

Chart

 
 

36.43

28.71

26.6

32.43

 
 
1month
3month
6month
1year
 
Total Return
ARWR
vs.
S&P500
 

 
1-week Return
+4.35%
 
+1.89%
 
 
5-week Return
-9.66%
 
+4.75%
 
 
10-week Return
+23.49%
 
+9.17%
 
 
 
 

Risk Analysis

ARWR Risk Analysis

 Earnings are forecast to decrease

 
 

ARWR Risk Level

This Indicator assigning risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
ARWR Risk Level
LOW
HIGH

Risk Volatility

 

ARWR has Low Risk Level

Click here to check what is your level of risk

 

ARWR Analysts Opinion

The company overall standing based on key factors, offering insights into analysts perspectives and market expectations. Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.00
 

ARWR Earnings Sentiment

 Below analyst estimate

 
 

Rating

×
 

Rating

NA
 
 

Momentum

×
 

Momentum

2.33
 

ARWR Momentum Analysis

 Price value has negative momentum

 

Activity

×
 

Activity

2.33
 
 

Future

×
 

Future

1.00
 

ARWR Future Sentiment

 Earnings are forecast to decrease

 
 

ARWR Analysts Opinion

ARWR Analysts opinion is negative and it remained unchanged from the past 3 months

 

ARWR Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
18%
Buy
Opinion
Trend
Score
Potential
Score
 
 
NA
0%
0%
 
On Track
On Track
On Track
 

ARWR Street Opinion 

ARWR Street view is unimpressive and have negative views on the near-term outlook

 

ARWR Performance Sentiment

Sentiments overview associated with the company events and the stock performance.
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
Contrasts the positive and negative sentiments surrounding the company performance.
 
18%
73%
Positive
Negative
2 out of 11
events present
8 out of 11
events present
 
 

ARWR Earnings

The Trailing Twelve Months (TTM) reflects 12-month period, providing rview of ARWR financial performance.

 
Millions of Dollars
TTM
2023
2022
CAGR
 

 
Total Revenue
182
241
243
-13.46%
 
 
Operating Expense
481
446
422
+6.76%
 
 
Operating Income
-299
-205
-179
-
 
 
Net Interest Income
-5
-3
5
 
 
Interest Expense
21
18
-
 
 
Interest Income
15
15
5
+73.21%
 
 
Other Income
1
2
1
0.00%
 
 
EPS
-1.92
-1.92
-1.67
-
 
 
Next Earnings Date: Apr 30, 2024
 
Highlights
Last Modify
Price
% Change

 
Concerns
Today
30.49
-3.50%
 
New Product
1 Week Ago
32.26
-0.92%
 
Weak Earnings
2 Weeks Ago
33.20
+3.69%
 
 

ARWR Latest News Feed













 
 
 
joker
 
 
 
StocksRunner

Explore our ARWR Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our ARWR Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 
 

Risk Analysis

 

ARWR Risk Analysis

 Earnings are forecast to decrease

 
 
 

ARWR Risk Level

 
 
 

The Indicator assigning risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
ARWR Risk Level
LOW
HIGH

Risk Volatility

 

ARWR has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

ARWR

 

Arrowhead Pharmaceuticals

$ 30.49

 
-$1.11 | -3.50%
 
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 31.84
 
 
MKT CAP
$ 3.78B
 
High
$ 32.48
 
 
VOL
$ 1.40M
 
Low
$ 30.29
 
 
AVG VOL
$ 1.22M
 
 
 

ARWR Analysis

  Sign in to view Arrowhead Pharmaceuticals (ARWR) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

36.43

28.71

26.6

32.43

 
 
1month
3month
6month
1year
 
Total Return
ARWR
vs.
S&P500
 

 
1-week Return
+4.35%
 
+1.89%
 
 
5-week Return
-9.66%
 
+4.75%
 
 
10-week Return
+23.49%
 
+9.17%
 
 
 

ARWR Analysts Opinion

Overall standing by considering key factors, reflecting analysts perspectives and market expectations. Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.00
 

ARWR Earnings Sentiment

 Below analyst estimate

 
 

Rating

×
 

Rating

NA
 
 

Momentum

×
 

Momentum

2.33
 

ARWR Momentum Sentiment

 Price value has negative momentum

 

Activity

×
 

Activity

2.33
 
 

Future

×
 

Future

1.00
 

ARWR Future Sentiment

 Earnings are forecast to decrease

 
 

ARWR Analysts Opinion

ARWR Analysts opinion is negative and it remained unchanged from the past 3 months

 

ARWR Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
18%
Buy
Opinion
Trend
Score
Potential
Score
 
 
NA
0%
0%
 
On Track
On Track
On Track
 

ARWR Street Opinion 

ARWR Street view is unimpressive and have negative views on the near-term outlook

 
ARWR Performance Sentiment
Sentiments overview associated with the company events and the stock performance.
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
Contrasts the positive and negative sentiments surrounding the company performance.
 
18%
73%
Positive
Negative
2 out of 11
events present
8 out of 11
events present
 

 

ARWR Earnings

The Trailing Twelve Months (TTM) data reflects the most recent 12-month period, providing overview of ARWR financial performance.

 
Millions of Dollars
TTM
2023
2022
CAGR
 

 
Total Revenue
182
241
243
-13.46%
 
 
Operating Expense
481
446
422
+6.76%
 
 
Operating Income
-299
-205
-179
-
 
 
Net Interest Income
-5
-3
5
 
 
Interest Expense
21
18
-
 
 
Interest Income
15
15
5
+73.21%
 
 
Other Income
1
2
1
0.00%
 
 
EPS
-1.92
-1.92
-1.67
-
 
 
Next Earnings Date: Apr 30, 2024
 
Highlights
Last Modify
Price
% Change

 
Concerns
Today
30.49
-3.50%
 
New Product
1 Week Ago
32.26
-0.92%
 
Weak Earnings
2 Weeks Ago
33.20
+3.69%
 
 
ARWR Latest News Feed

On its third weekend Helldivers 2 actually worked. It took just over two weeks and some loss of sleep but Helldivers 2 the smash hit co-op shooter from PlayStation and Swedens Arrowhead Game Studio now actually works. Which is to say the game cruised thro

Today

Activity

Helldivers 2 is more than just a great Starship Troopers game. Game developers have long sought to make a great Starship Troopers video game but no ones ever come as close as Arrowhead Game Studios recent release Helldivers 2. Paul Verhoevens film Starshi

Tue Feb 13, 2024

Activity

The Helldivers 2 devs are fixing the game. Heres a tiny window into what its like for a smaller developer to have a game theyre working on blow up. Arrowhead Game Studios bug-squashing third-person shooter Helldivers 2 launched simultaneously on PC and Pl

Mon Feb 12, 2024

Activity

cracking the code: understanding analyst reviews for arrowhead pharma. analysts'. ratings for arrowhead pharma (nasdaq:) over the last quarter vary from ish to bearish as provided by 6 analysts. the table below offers a condensed view of their recent

Wed Feb 7, 2024

Potential

arrowhead pharmaceuticals gaap eps of -$1.24 misses by $0.43 revenue of $3.55m misses by $26.09m.

Tue Feb 6, 2024

Earnings

arrowhead stock slides 6% as fiscal q1 report falls short of estimates.

Tue Feb 6, 2024

Momentum

notable two hundred day moving average cross - arwr. in trading on friday shares of arrowhead pharmaceuticals inc (symbol: arwr) crossed below their 200 day moving average of $31.12 changing hands as low as $30.65 per share. arrowhead pharm

Fri Feb 2, 2024

Momentum

chiefs-dolphins wild card game ticket prices plunge along with temperatures to $30. fans sit in the snow before an afc divisional round playoff game game at arrowhead stadium chiefs fans are used to the cold but not this kind of cold. temperatures for sat

Fri Jan 12, 2024

Momentum

arrowhead completes $450 million stock offering.

Fri Jan 5, 2024

Activity

arrowhead pharma gains 6% prices $450 mln offering of shares. (rttnews) - arrowhead pharmaceuticals inc. (arwr) shares were gaining more than 6 percent on wednesday after pricing of approximately 15.8 million shares at $28.50 per share to raise

Wed Jan 3, 2024

Activity

arrowhead pharmaceuticals prices $450m common stock offering.

Wed Jan 3, 2024

Activity

 
 
 
 
 

Score Tracker

 
 
 
Based on 11 events in the last 90 days from financial news and social media. Last updated Feb 26, 2024 23:13 Wall St. time
 
 

ARWR Total Score

 
 
 
 
 
 
 
StocksRunner

Discover ARWR Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of ARWR. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our ARWR Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

ARWR Stock trends

ARWR Stock performance

ARWR Stock analysis

ARWR investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker